XRD 0394
Alternative Names: XRD-0394Latest Information Update: 28 Sep 2024
At a glance
- Originator XRad Therapeutics
- Class Antineoplastics; Radioprotectives; Small molecules
- Mechanism of Action Ataxia telangiectasia mutated protein inhibitors; DNA-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours(First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in USA (PO, Capsule)
- 05 Apr 2024 Adverse events and pharmacokinetic data from a phase I trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)